


Product Name : Clifutinib
Cat. No. : PC-24405
CAS No. : 1862226-99-0
Molecular Formula : C₂₉H₃₄N₄O₄
Molecular Weight : 502.62
Target : FLT3
Solubility : 10 mM in DMSO



CAS: 1862226-99-0

Biological Activity

Clifutinib (HEC73543) is potent, selective **FLT3-ITD** (internal tandem duplication mutations of FLT3) inhibitor with biochemical IC₅₀ of 15.1 nM, exhibits significant antiproliferative activity against Ba/F3-FLT3-ITD cells with IC₅₀ of 0.9 nM.

Clifutinib potently suppresses proliferation of MV-4-11 and MOLM-13 AML cells harboring FLT3-ITD with IC₅₀ of 1.5 and 1.4 nM, respectively.

Clifutinib only exhibits >80% inhibition against 12 out of 414 kinases at 1 μM, does not inhibit KIT kinase (IC₅₀ = 1790 nM).

Clifutinib shows minimal or no antiproliferative effects were observed against FLT3-ITD-negative cell lines such as RS4;11, HL-60, MOLT-4, RPMI8226, and K562.

Clifutinib demonstrates significant antiproliferative activity against BaF3 cells driven by the most common FLT3-TKD mutations (D835Y, D835H, and D835V), with IC₅₀ values of 5.4, 10.9, and 37.4 nM, respectively.

Clifutinib exhibits favorable antiproliferative activity against FLT3-ITD mutant leukemia cells but not against FLT3 wild-type cells.

Clifutinib induces apoptosis in FLT3-ITD mutant AML cells, inhibits the phosphorylation of FLT3, ERK, AKT, and STAT5 in a dose-dependent manner without affecting their total protein levels.

Clifutinib (1.5 or 4.5 mg/kg, orally once daily) exhibited rapid and near-complete tumor regression, with no tumor rebound observed during the 31-day post-treatment period in MV-4-11 and MOLM-13 xenograft tumor models.

References

Liu B, et al. *J Med Chem*. 2025 Apr 11. doi: 10.1021/acs.jmedchem.4c03023.

Cliff Cheng, et al. *Cancer Res* (2017) 77 (13_Supplement): 2093.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com